Tabell
Hovedbudskap |
|
- 1.
Haijeh RA, Reingold A, Weil A et al. Toxic shock syndrome in the United States: surveillance update, 1979 – 1996. Emerg Infect Dis 1999; 5: 807 – 10.
- 2.
Lehn N, Schaller E, Wagner H et al. Frequency of toxic shock syndrome toxin and enterotoxin-producing clinical isolates of Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1995; 14: 43 – 6.
- 3.
De Boer ML, Kum WW, Chow AW. Staphylococcal aureus isogenic mutant, deficient in toxic shock syndrome toxin-1 but not staphylococcal enterotoxin A production, exhibits attenuated virulence in tampon-associated vaginal infection model of toxic shock syndrome. Can J Microbiol 1999; 45: 250 – 6.
- 4.
Reingold AL, Hargrett NT, Shands KN et al. Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med 1982; 96 (del 2): 875 – 80.
- 5.
Andrews MM, Parent EM, Barry M et al. Recurrent nonmentrual toxic shock syndrome: Clinical manifestations, diagnosis, and treatment. Clin Infect Dis 2001; 32: 1470 – 9.
- 6.
Parsonnet J, Modern PA, Giacobbe K. Effect of subinhibitory concentrations of antibiotics on production of toxic shock syndrome toxin-1 (TSST-1). Program and abstracts of the 32nd meeting of the Infectious Disease Society of America. Orlando, FL: Infectious Disease Society of America, 1994.
- 7.
Keller MA, Stiehm ER. Passive immunity in prevention and treatment in infectious diseases. Clin Microbiol Rev 2000; 13: 602 – 24.
- 8.
Todd JK, Ressman M, Castron SA et al. Corticosteroid therapy in patients with toxic shock syndrome. JAMA 1984; 252: 3399 – 402.
- 9.
Parsonnet J, Hansmann MA, Delaney ML et al. Prevalence of toxic shock syndrome toxin-1 producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 2005; 43: 4628 – 34.
- 10.
Krakauer T, Stiles B. Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release. Clin Diagn Lab Immunol 1999; 6: 594 – 8.